14 research outputs found

    Perifolliculitis Capitis Abscedens et Suffodiens Treated with Anti-tumor Necrosis Factor-alpha ā€“ Possible New Treatment Option

    Get PDF
    The case of a 26-year-old male patient with perifolliculitis capitis abscedens et suffodiens (PCAS) who later developed hidradenitis suppurativa (HS) and exacerbation of acne is presented. The patient did not respond well to conventional treatment including isotretinoin and oral antibiotics. Quality of life was significantly impaired. After introduction of anti-tumor necrosis factor-alpha (TNF-Ī±) treatment, the patientā€™s clinical picture improved dramatically and quality of life increased. The treatment has been well tolerated by the patient for 15 months at time of writing this report.Ā </p

    The incidence of fatigue that symptoms in malignant diseases

    Get PDF
    Umor je jedan od najčeŔćih simptoma u bolesnika sa zloćudnom bolesti. Može se javiti tijekom cjelokupnog trajanja bolesti: od dijagnoze, tijekom liječenja, a može trajati mjesecima, pa i godinama nakon zavrÅ”etka terapije. Prevalencija se kreće od 15% do 90% ovisno o koriÅ”tenim metodama za mjerenje umora i karakteristikama bolesti i liječenja. Umor u onkoloÅ”kih bolesnika značajno utječe na kvalitetu života, fizičko funkcioniranje i psihičko zdravlje. Ima jači negativni utjecaj na svakodnevni život bolesnika od ostalih simptoma povezanih sa zloćudnom bolesti. Umor također može imati negativan učinak na ishod liječenja smanjujući preživljenje, stoga je neophodno rano otkrivanje i odgovarajuća intervencija. Ipak simptom umora u ovih bolesnika kontinuirano je zanemaren, nedovoljno prijavljen i liječen. Uzroci umora u bolesnika sa zloćudnom bolesti su multifaktorijalni i slabo razjaÅ”njeni, i njegova terapija često stvara velike poteÅ”koće liječnicima i bolesnicima. S obzirom na to da je umor subjektivan simptom, najbolje se može procijeniti s pomoću upitnika koje ispunjavaju sami bolesnici. Specifično liječenje provodi se ako su identificirani uzrok ili pridonoseći čimbenici. Nespecifično liječenje umora uključuje nefarmakoloÅ”ke metode poput psihosocijalnih intervencija, tjelesne aktivnosti, terapije poremećaja spavanja, akupunkture i joge, dok farmakoloÅ”ko liječenje uključuje psihostimulanse, antidepresive i kortikosteroide. Ovaj rad predstavlja pregled prevalencije, patogeneze, dijagnostike i mogućeg liječenja simptoma umora u bolesnika sa zloćudnom bolesti.Fatigue is one of the most prevalent symptoms in cancer patients. It can occur at any time throughout the course of the disease: at time of diagnosis, during treatment and even months to years after completion of therapy. Prevalence estimates have ranged from 15% to 90% of all cancer patients, depending on methods used for measuring fatigue and patient group characteristics. Cancer-related fatigue (CRF) has an adverse effect on quality of life, physical functioning and can significantly affect daily activities, in some cases more than any other cancer-related symptom. It can also be a risk factor for reduced survival so awareness, early diagnosis and effective intervention are necessary. Despite its impact on patients and caregivers, fatigue is underreported and underrecognized, and remains undertreated among patients with cancer. The causes of CRF are multifactorial and poorly understood. This is the why alleviating CRF is a challenge for physicians and patients. Management of fatigue is cause-specific when conditions known to contribute to fatigue can be identified and treated. Otherwise treatment modalities for CRF are nonspecific and include nonpharmacologic interventions such as psychosocial interventions, exercise, sleep therapy, acupuncture and yoga, while pharmacologic interventions include psychostimulants, antidepressants and corticosteroids. This paper focuses on prevalence, pathogenesis, assessment and possible treatment of cancer-related fatigue

    The incidence of fatigue that symptoms in malignant diseases

    Get PDF
    Umor je jedan od najčeŔćih simptoma u bolesnika sa zloćudnom bolesti. Može se javiti tijekom cjelokupnog trajanja bolesti: od dijagnoze, tijekom liječenja, a može trajati mjesecima, pa i godinama nakon zavrÅ”etka terapije. Prevalencija se kreće od 15% do 90% ovisno o koriÅ”tenim metodama za mjerenje umora i karakteristikama bolesti i liječenja. Umor u onkoloÅ”kih bolesnika značajno utječe na kvalitetu života, fizičko funkcioniranje i psihičko zdravlje. Ima jači negativni utjecaj na svakodnevni život bolesnika od ostalih simptoma povezanih sa zloćudnom bolesti. Umor također može imati negativan učinak na ishod liječenja smanjujući preživljenje, stoga je neophodno rano otkrivanje i odgovarajuća intervencija. Ipak simptom umora u ovih bolesnika kontinuirano je zanemaren, nedovoljno prijavljen i liječen. Uzroci umora u bolesnika sa zloćudnom bolesti su multifaktorijalni i slabo razjaÅ”njeni, i njegova terapija često stvara velike poteÅ”koće liječnicima i bolesnicima. S obzirom na to da je umor subjektivan simptom, najbolje se može procijeniti s pomoću upitnika koje ispunjavaju sami bolesnici. Specifično liječenje provodi se ako su identificirani uzrok ili pridonoseći čimbenici. Nespecifično liječenje umora uključuje nefarmakoloÅ”ke metode poput psihosocijalnih intervencija, tjelesne aktivnosti, terapije poremećaja spavanja, akupunkture i joge, dok farmakoloÅ”ko liječenje uključuje psihostimulanse, antidepresive i kortikosteroide. Ovaj rad predstavlja pregled prevalencije, patogeneze, dijagnostike i mogućeg liječenja simptoma umora u bolesnika sa zloćudnom bolesti.Fatigue is one of the most prevalent symptoms in cancer patients. It can occur at any time throughout the course of the disease: at time of diagnosis, during treatment and even months to years after completion of therapy. Prevalence estimates have ranged from 15% to 90% of all cancer patients, depending on methods used for measuring fatigue and patient group characteristics. Cancer-related fatigue (CRF) has an adverse effect on quality of life, physical functioning and can significantly affect daily activities, in some cases more than any other cancer-related symptom. It can also be a risk factor for reduced survival so awareness, early diagnosis and effective intervention are necessary. Despite its impact on patients and caregivers, fatigue is underreported and underrecognized, and remains undertreated among patients with cancer. The causes of CRF are multifactorial and poorly understood. This is the why alleviating CRF is a challenge for physicians and patients. Management of fatigue is cause-specific when conditions known to contribute to fatigue can be identified and treated. Otherwise treatment modalities for CRF are nonspecific and include nonpharmacologic interventions such as psychosocial interventions, exercise, sleep therapy, acupuncture and yoga, while pharmacologic interventions include psychostimulants, antidepressants and corticosteroids. This paper focuses on prevalence, pathogenesis, assessment and possible treatment of cancer-related fatigue

    Are Multiple Primary Melanomas a Rare Entity?

    Get PDF
    Multiple primary melanomas are described in literature as a relatively rare, but nevertheless well known entity. The incidence varies from 0.2 to 23 % worldwide. Many risk factors for the development of multiple primary melanomas have been observed, including multiple dysplastic nevi, positive family history, over 60 years of age at diagnosis of first melanoma, male sex and white race. The first primary melanoma in patients with multiple primary melanomas has the greatest tumour thickness, while subsequent melanomas are usually significantly less invasive, most probably due to strict follow-up schedules and regular self-examinations. We will report of two patients with multiple primary melanomas and follow-up methods for early detection of other primary melanomas

    Notalgia paresthetica

    Get PDF
    Notalgia paresthetica is a common, although under-recognized condition characterized by localized chronic pruritus in the upper back, most often affecting middle-aged women. Apart from pruritus, patients may present with a burning or cold sensation, tingling, surface numbness, tenderness and foreign body sensation. Additionally, patients often present with hyperpigmented skin at the site of symptoms. The etiology of this condition is still poorly understood, although a number of hypotheses have been described. It is widely accepted that notalgia paresthetica is a sensory neuropathy caused by alteration and damage to posterior rami of thoracic spinal nerves T2 through T6. To date, no well-defined treatment has been found, although many treatment modalities have been reported with varying success, usually providing only temporary relief.Notalgia paresthetica je učestalo, iako slabo prepoznato stanje koje obilježava lokalizirani kronični pruritus gornjeg dijela leđa, a najčeŔće se javlja u žena srednje životne dobi. Uz svrbež u bolesnika se također može javiti osjećaj žarenja ili hladnoće, trnci, utrnulost, osjetljivost i osjećaj stranog tijela. Uz to, na mjestu simptoma često se javlja područje hiperpigmentirane kože. Iako postoji viÅ”e hipoteza, etiologija ove bolesti slabo je poznata. Opće je prihvaćeno da je notalgia paresthetica senzorna neuropatija uzrokovana oÅ”tećenjem stražnjih ogranaka torakalnih kralježničnih živaca od T2 do T6. Unatoč mnogim različitim terapijskim metodama koje su bile promjenjivoga uspjeha i najčeŔće pružale privremeno olakÅ”anje, do danas nema uspjeÅ”noga liječenja ove bolesti

    Effect of allergens and irritants on levels of natural moisturizing factor and corneocyte morphology

    Get PDF
    BACKGROUND: The irritant sodium lauryl sulfate (SLS) is known to cause a decrease in the stratum corneum level of natural moisturizing factor (NMF), which in itself is associated with changes in corneocyte surface topography. ----- OBJECTIVE: To explore this phenomenon in allergic contact dermatitis. ----- METHODS: Patch testing was performed on patients with previously positive patch test reactions to potassium dichromate (Cr), nickel sulfate (Ni), methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI), or p-phenylenediamine. Moreover, a control (pet.) patch and an irritant (SLS) patch were applied. After 3ā€‰days, the stratum corneum from tested sites was collected, and NMF levels and corneocyte morphology, expressed as the amount of circular nanosize objects, quantified according to the Dermal Texture Index (DTI), were determined. ----- RESULTS: Among allergens, only MCI/MI reduced NMF levels significantly, as did SLS. Furthermore, only MCI/MI caused remarkable changes at the microscopic level; the corneocytes were hexagonal-shaped with pronounced cell borders and a smoother surface. The DTI was increased after SLS exposure but not after allergen exposure. ----- CONCLUSIONS: MCI/MI significantly decreased NMF levels, similarly to SLS. The altered corneocyte morphology suggests that skin barrier damage plays a role in the pathogenesis of MCI/MI contact allergy. The DTI seems to differentiate reactions to SLS from those to the allergens tested, as SLS was the only agent that caused a DTI increase
    corecore